 MENLO PARK, Calif.--BUSINESS WIRE--Intersect ENT, Inc. Nasdaq: XENT, a global ear, nose and throat ENT medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the companys PROPEL Contour mometasone furoate sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products available for commercialization inclusive of PROPEL and PROPEL Mini. PROPEL Contour 